Associate Digital Marketing Manager

Parse Biosciences and bit.bio announce landmark alliance. Business Wire Published May 27, 2026 Article content Unlocking Cell Fate: Alliance will power AI-driven predictive medicine and human cell manufacturing Article content SEATTLE - Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced an alliance with bit.bio to create a comprehensive map of transcription factor-driven cell identity, encompassing both cell state and cell fate. This map will serve as the foundational blueprint for developing highly accurate, human-relevant models at scale. By precisely mimicking in vivo biological responses, these models will significantly advance predictive drug discovery and therapeutic development. Article content Advertisement 1 Story continues below This advertisement has not loaded yet, but your article continues below. Article content This collaboration doesn't just generate data; it provides a foundational map for bit.bio to scale human-relevant models and feed predictive AI systems, moving the entire field closer to reliably replicating and predicting human biology. Article content The alliance will leverage cutting-edge techniques in massively parallel causal transcriptomics, which allows scientists to test thousands of genetic variables simultaneously to understand what drives cell behavior. bit.bio will contribute its industry-leading cell programming technology, opti-ox(TM), as well as its proprietary Discovery platform, The Cell Foundry(TM), and Parse its scalable single cell technology, Evercode(TM). The result will build on existing proprietary data to an unprecedented bit.bio dataset that maps how specific genetic inputs lead to specific biological outputs. Ultimately, this dataset will guide not only bit.bio but the wider industry on how therapies are designed and human cells manufactured at scale, while also feeding AI models that can predict how cells respond to drugs or disease. Article content Top Stories Interested in more newsletters? Browse here. Article content "Cells operate on code, and by mapping how specific transcription factors dictate cell fate, we are unlocking that operating system. This collaboration doesn't just generate data; it provides a foundational map for bit.bio to scale human-relevant models and feed predictive AI systems, moving the entire field closer to reliably replicating and therefore predicting human biology," remarks Przemek Obloj, CEO of bit.bio. Article content "Researchers need insights that they can translate into impact," states Charlie Roco, PhD, Co-founder and Chief Technology Officer at Parse Biosciences. "Our close alliance with bit.bio will create foundational datasets that establish clear causal links between genetic changes and biological outcomes, the kind of information that predictive medicine needs but has rarely had." Article content To learn more about how these data will shape the future of predictive biology modeling and manufacturing, attend the Parse webinar on June 17 at 7:00 AM Pacific Time. Article content About bit.bio Article content bit.bio, the global leader in cell programming technology, is creating functional, human-relevant cells and models at industrial scale to accelerate research, drug discovery and development, while facilitating the adoption of New Approach Methodologies (NAMs). Product development is fuelled by its AI-enabled discovery platform that identifies unique transcription factor combinations to program desired cell types, and its patented opti-ox(TM) technology that precisely converts induced pluripotent stem cells (iPSCs) into these cell types assuring unprecedented purity, consistency, and scalability. bit.bio's expanding ioCells portfolio comprises more than 50 products, including ioWild Type Cells, ioDisease Model Cells, ioCRISPR-Ready Cells, and ioTracker Cells. Article content Advertisement 2 Story continues below Article content Since spinning out from the University of Cambridge in 2016, bit.bio has raised over $200m from leading investors including Arch Venture, BlueYard Capital, Charles River Laboratories, Foresite Capital, M&G, Milky Way, National Resilience, and Tencent. Article content About Parse Biosciences Article content Parse Biosciences, a QIAGEN company, is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. Article content View source version on businesswire.com: Article content Advertisement 1

Parse Biosciences, a QIAGEN company, has launched Evercode Whole Transcriptome FFPE kits, enabling whole transcriptome single-cell RNA sequencing from formalin-fixed, paraffin-embedded samples for the first time. The technology addresses a major limitation in accessing FFPE samples, which represent the world's largest repository of clinically annotated tissue. Previously, RNA degradation in FFPE samples forced researchers to rely on predefined gene panels, limiting full transcriptome analysis. Parse's solution uses a novel split-pool combinatorial barcoding approach and proprietary reverse transcription-based RNA capture chemistry designed for compromised RNA. The technology allows cancer, neuroscience and translational researchers to access single-cell resolution across the full transcriptome for new and archived FFPE samples. The kits are now shipping to customers.

Maximize every sample: how Evercode v4 redefines performance in Whole Transcriptome profiling. Published: 24 Mar 2026 Parse Biosciences, a part of QIAGEN known as the leading provider of scalable and accessible single-cell sequencing solutions, has launched the new Evercode(TM) Whole Transcriptome v4 product line today. This new product improves scalability, boosts sensitivity, and streamlines the workflow for single-cell RNA sequencing. Precision at scale: Parse Biosciences unveils v4 chemistry with unmatched gene sensitivity. The Evercode v4 system features impressive scalability, supporting up to five million cells and 384 samples in one run. This allows researchers to perform large studies while maintaining sample resolution. The enhanced chemistry improves gene detection per cell and reduces the number of sequencing reads needed, which helps lower overall sequencing costs. According to Precedence Research, the Specimen Retrieval Market size accounted for USD 316.22 billion in 2025 and is predicted to increase from USD 330.86 billion in 2026 to approximately USD 497.22 billion by 2035, expanding at a CAGR of 4.63% from 2026 to 2035 as demand grows for adoption of minimally invasive surgery, focus on patient safety and infection control and growing prevalence of chronic diseases. A new magnetic bead-based workflow has been introduced, replacing the traditional centrifugation steps and improving cell recovery by up to 75%. This innovation allows researchers to gather more data from limited or precious samples. The optimized process reduces hands-on time and the number of pipetting steps, and is designed to support laboratory automation, making it suitable for labs with different levels of experience in single-cell techniques. Capture every detail: enhanced Retrieval for rare cell discovery in Evercode v4. Additionally, Evercode v4 effectively removes off-target reads, which improves gene detection per cell, even at lower sequencing depths and costs compared to other options. With its high sensitivity, Evercode v4 offers better biological resolution for researchers studying rare cell types or genes with low expression levels. The chemistry behind Evercode Whole Transcriptome v4 is present across the entire Evercode Whole Transcriptome product range, which features Evercode Fixation and experiments carried out in Parse's GigaLab. "From the beginning, our goal has been to provide the research community with single-cell technology that is scalable, accessible, and high-performing," said Charlie Roco, PhD, Co-founder and Chief Technology Officer of Parse Biosciences. "Evercode v4 reflects years of development and direct feedback from its users, marking a major improvement in cell recovery and sensitivity, along with a simpler workflow. A recent report by Precedence Research highlights that the Specimen Retrieval Market is benefiting from technological advancements in robotic-assisted devices, growing demand for patient safety and infection control, and increasing healthcare infrastructure investments in emerging markets.